Full-Time

Senior Engineer

Microfluids and Perfusion Interfaces

e184

e184

1-10 employees

VC funding HealthTech, FinTech, and SaaS

No salary listed

Portland, OR, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)

Get referred to e184

See people who can refer or advise you

Requirements
  • PhD or MS with significant experience in Bioengineering, Mechanical Engineering, Chemical Engineering, Biomedical Engineering, or a related field
  • Demonstrated experience designing or operating microfluidic or perfusion-based culture systems
  • Strong understanding of fluid dynamics, mass transport, and gas exchange in biological systems
  • Hands-on experience with device prototyping and experimental validation
  • Ability to independently drive complex technical projects from concept to implementation
  • Comfortable working in a fast-paced, iterative startup environment
  • Strong organizational and documentation skills
Responsibilities
  • Lead perfusion system development: Design and build microfluidic and perfusion platforms that support long-term cell and tissue culture through controlled nutrient delivery, gas exchange, and waste management
  • Engineer culture interfaces: Develop biocompatible fluidic architectures and culture chambers that maintain stable physiological conditions while enabling imaging, sampling, and experimental manipulation
  • Optimize fluid and gas transport: Model and experimentally validate flow dynamics, oxygenation, and mass transport to ensure stable culture environments across varying developmental stages and tissue scales
  • Prototype and iterate rapidly: Design, fabricate, and test devices using microfabrication and rapid prototyping approaches (e.g., CNC machining, laser cutting, soft lithography, additive manufacturing), iterating based on biological performance
  • Collaborate across disciplines: Work closely with developmental biologists to translate biological constraints into engineering specifications and with software/data teams to integrate monitoring and experimental control systems
Desired Qualifications
  • Experience working with mammalian cell culture or biological interfaces
  • Experience developing long-term perfusion or organ-on-chip culture systems
  • Background in microphysiological systems, tissue engineering, or bioreactor design
  • Experience designing oxygenation or gas exchange interfaces for biological systems
  • Microfabrication experience (soft lithography, PDMS devices, micromachining, microfluidic bonding techniques)
  • Experience integrating sensors, automation, or closed-loop control systems
  • Prior startup or early-stage technology development experience

e184 is a venture capital investor focusing on HealthTech, FinTech, and SaaS in the United States, providing capital to startups to help them grow. It uses a multi-stage VC model, investing equity across early to late stages and aiming for exits such as IPOs or acquisitions, guided by leadership that coordinates capital allocation and leverages expertise in payments, banking, crypto, and investments. The firm differentiates itself through its sector focus combined with flexible stages and a willingness to explore additional verticals, using its payments, banking, and crypto know-how to guide portfolio value. Its goal is to deliver high-growth returns for investors by funding innovative startups, supporting their scale, and exiting positions profitably, while continually seeking new opportunities across industries.

Company Size

1-10

Company Stage

N/A

Total Funding

$5.8M

Headquarters

Kentucky

Founded

2023

Get referred to e184

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The 2026 site updates show active expansion into BCI, artificial womb, and repro labs.
  • Sponsoring neuroscience events in London and the UK strengthens founder access and credibility.
  • Paterna BioSciences gives e184 an operating proof point for specialized, high-conviction investing.

What critics are saying

  • PitchBook shows only one disclosed investment, Paterna BioSciences, since 2024.
  • Leadership inconsistency around Alex Pisanov versus Kirill Eves signals messy governance and branding.
  • The firm depends on niche reproductive and neurotech outcomes; one failed thesis kills fundraising.

What makes e184 unique

  • e184 pivots from general VC toward neurotech and reproduction, per 2026 website pages.
  • Founder Kirill Eves anchors a tightly controlled platform with Marianna Krell and Peter Zhegin.
  • Field-building events like the 2026 Global Neurotech Hackathon create proprietary deal flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Remote Work Options

Flexible Work Hours

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Equity

Company News

EIN News
Oct 28th, 2024
Paterna BioSciences Secures Seed Funding to Advance Groundbreaking Male Fertility Treatment

$6 million oversubscribed seed investment to advance pioneering in vitro spermatogenesis science, offers new hope for people struggling with infertility.